

South East London Area Prescribing Committee Formulary recommendation

Reference	043
Intervention:	Daily tadalafil (Cialis®) tablets for the treatment of erectile dysfunction where when required sildenafil and when required tadalafil have failed (Tadalafil is a phosphodiesterase type 5 enzyme (PDE5) inhibitor)
Date of Decision	November 2015
Date of Issue:	December 2015
Recommendation:	Grey – not recommended for prescribing in South East London
Further Information	<ul style="list-style-type: none"> • The South East London APC is unable to support the use of daily tadalafil (usually 5mg or 2.5mg daily) for the treatment of erectile dysfunction in patients who have failed to respond to when required (prn) sildenafil or when required tadalafil. • Daily tadalafil has been grey listed in SEL because a single common treatment pathway for the management of erectile dysfunction in this setting has not been developed and submitted by local specialists*. • Daily tadalafil in this setting will be grey listed until the treatment pathway is submitted to and approved by the Committee. <p>* Development of a South-East London wide, cross-specialty pathway was requested by the Committee in October 2014 following a formulary submission from local clinicians for the use of daily tadalafil in this setting.</p>
Shared Care/Transfer of care document required:	N/A
Cost Impact for agreed patient group	N/A
Usage Monitoring & Impact Assessment	Trusts – monitor non-formulary requests
	CCGs – monitor impact data
Evidence reviewed	N/A

NOTES:

- Area Prescribing Committee recommendations and minutes are available publicly on member CCG websites.
- This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if a submission is received or new NICE guidelines or technology appraisals are issued.
- Not to be used for commercial or marketing purposes. Strictly for use within the NHS.**